Pulmonary hypertension due to lung disease and/or hypoxia

Clinics in Chest Medicine

Volumn 34, Issue 4, 2013, Pages 695-705

  Nathan, Steven D ^a   Hassoun, Paul M ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Echocardiography; Interstitial lung disease; Obstructive lung disease; Prognosis; Pulmonary hypertension; Respiratory function tests; Sarcoidosis

Indexed keywords

AMBRISENTAN; BOSENTAN; CARBACYCLIN DERIVATIVE; PLACEBO; SILDENAFIL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; FIBROSING ALVEOLITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOXIA; INTERSTITIAL PNEUMONIA; LANGERHANS CELL HISTIOCYTOSIS; LUNG PARENCHYMA; LUNG SARCOIDOSIS; LYMPHANGIOLEIOMYOMATOSIS; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY LANGERHANS CELL HISTIOCYTOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SLEEP DISORDERED BREATHING;

ECHOCARDIOGRAPHY; INTERSTITIAL LUNG DISEASE; OBSTRUCTIVE LUNG DISEASE; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS;

ANOXIA; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES;

EID: 84888198407     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.08.004     Document Type: Review

References (98)

1. Shlobin O.A., Nathan S.D. Pulmonary hypertension secondary to interstitial lung disease. Expert Rev Respir Med 2011, 5:179-189.
2. Thabut G., Dauriat G., Stern J.B., et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005, 127:1531-1536.
3. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. JAm Coll Cardiol 2009, 54:S43-S54.
4. Chaouat A., Naeije R., Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008, 32:1371-1385.
5. Chaouat A., Bugnet A.S., Kadaoui N., et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172:189-194.
6. Cuttica M.J., Kalhan R., Shlobin O.A., et al. Functional impact of pulmonary hypertension in patients with COPD listed for lung transplant. Respir Med 2010, 104:1877-1882.
7. Chatila W.M., Thomashow B.M., Minai O.A., et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5:549-555.
8. Falk J.A., Kadiev S., Criner G.J., et al. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5:543-548.
9. Scharf S.M., Iqbal M., Keller C., et al. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002, 166:314-322.
10. Weitzenblum E., Hirth C., Ducolone A., et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981, 36:752-758.
11. Mykland Hilde J., Skjorten I., Hansteen V., et al. Hemodynamic responses to exercise in patients with COPD. Eur Respir J 2013, 41:1031-1041.
12. Gartman E.J., Blundin M., Klinger J.R., et al. Initial risk assessment for pulmonary hypertension in patients with COPD. Lung 2012, 190:83-89.
13. Lettieri C.J., Nathan S.D., Barnett S., et al. Prevalence and outcomes of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. Chest 2006, 129:746-752.
14. Nadrous H.F., Pellikka P.A., Krowka M.J., et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005, 128:2393-2399.
15. Shorr A.F., Wainright J.L., Cors C.S., et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting transplant. Eur Respir J 2007, 30:715-721.
16. Raghu G., Behr J., Brown K.K., et al. Artemis-IPF: treatment of idiopathic pulmonary fibrosis with ambrisentan, a selective antagonist of the Endothelin A receptor: a randomized trial. Ann Intern Med 2013, 158:641-649.
17. Swanson K.L., Utz J.P., Krowka M.J. Doppler echocardiography-right heart catheterization relationships in patients with idiopathic pulmonary fibrosis and suspected pulmonary hypertension. Med Sci Monit 2008, 14:177-182.
18. Nathan S.D., Shlobin O.A., Ahmad S., et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008, 76:288-294.
19. Hamada K., Nagai S., Tanaka S., et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007, 131:650-656.
20. Zisman D.A., Karlamangla A.S., Ross D.J., et al. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007, 132:773-779.
21. Song J.W., Song J.K., Kim D.S. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med 2009, 103:180-186.
22. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003, 167:735-740.
23. Nathan S.D., Barnett S.D., Saggar R., et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respir Med 2008, 102:1305-1310.
24. Nathan S.D., Shlobin O.A., Ahmad S., et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007, 131:657-663.
25. Jankowich M.D., Rounds S.I. Combined pulmonary fibrosis and emphysema syndrome. Chest 2012, 141:222-231.
26. Oswald-Mammosser M., Weitzenblum E., Quoix E., et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995, 107:1193-1198.
27. Sertogullarindan B., Gumrukcuoglu H.A., Sezgi C., et al. Frequency of pulmonary hypertension in patients with COPD due to biomass smoke and tobacco smoke. Int J Med Sci 2012, 9:406-412.
28. Sulica R., Teirstein A.S., Kakarla S., et al. Distinctive clinical, radiographic and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005, 128:1483-1489.
29. Handa T., Nagai S., Miki S., et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006, 129:1246-1252.
30. Gluskowski J., Hawrylkiewicz I., Zych D., et al. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration 1984, 46:26-32.
31. Baughman R.P., Engel P.J., Meyer C.A., et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23:108-116.
32. Shorr A.F., Helman D.L., Davies D.B., et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005, 25:783-788.
33. Baughman R.P., Engel P.J., Taylor L., et al. Survival in sarcoidosis-associated pulmonary hypertension:the importance of hemodynamic evaluation. Chest 2010, 138:1078-1085.
34. Latsi P.I., du Bois R.M., Nicholson A.G., et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168:531-537.
35. Kawahara Y., Taniguchi T., Kadou T., et al. Elevated pulmonary arterial pressure in pulmonary lymphangiomyomatosis. Jpn J Med 1989, 28:520-522.
36. Taveira-DaSilva A.M., Hathaway O.M., Sachdev V., et al. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 2007, 132:1573-1578.
37. Taveira-DaSilva A.M., Stylianou M.P., Hedin C.J., et al. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2003, 168:1427-1431.
38. Kiakouama L., Cottin V., Etienne-Mastroianni B., et al. Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. Eur Respir J 2010, 36:202-204.
39. Lazor R., Etienne-Mastroianni B., Khouatra C., et al. Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy. Thorax 2009, 64:274-275.
40. Dauriat G., Mal H., Thabut G., et al. Lung transplantation for pulmonary Langerhans' cell histiocytosis: a multicenter analysis. Transplantation 2006, 81:746-750.
41. Fartoukh M., Humbert M., Capron F., et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000, 161:216-223.
42. Chaouat A., Weitzenblum E., Krieger J., et al. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest 1996, 109:380-386.
43. Sajkov D., McEvoy R.D. Obstructive sleep apnea and pulmonary hypertension. Prog Cardiovasc Dis 2009, 51:363-370.
44. Sajkov D., Cowie R.J., Thornton A.T., et al. Pulmonary hypertension and hypoxemia in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1994, 149:416-422.
45. Sanner B.M., Doberauer C., Konermann M., et al. Pulmonary hypertension in patients with obstructive sleep apnea syndrome. Arch Intern Med 1997, 157:2483-2487.
46. Bady E., Achkar A., Pascal S., et al. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax 2000, 55:934-939.
47. Laaban J.P., Cassuto D., Orvoen-Frija E., et al. Cardiorespiratory consequences of sleep apnoea syndrome in patients with massive obesity. Eur Respir J 1998, 11:20-27.
48. Usui Y., Takata Y., Inoue Y., et al. Severe obstructive sleep apnea impairs left ventricular diastolic function in non-obese men. Sleep Med 2013, 14:155-159.
49. Minai O.A., Ricaurte B., Kaw R., et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 2009, 104:1300-1306.
50. Garvey J.F., Taylor C.T., McNicholas W.T. Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur Respir J 2009, 33:1195-1205.
51. Lavie L., Lavie P. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J 2009, 33:1467-1484.
52. Ryan S., Taylor C.T., McNicholas W.T. Predictors of elevated nuclear factor-kappab-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006, 174:824-830.
53. Somers V.K., Dyken M.E., Clary M.P., et al. Sympathetic neural mechanisms in obstructive sleep apnea. JClin Invest 1995, 96:1897-1904.
54. Eisenberg E., Zimlichman R., Lavie P. Plasma norepinephrine levels in patients with sleep apnea syndrome. NEngl J Med 1990, 322:932-933.
55. Marrone O., Bellia V., Ferrara G., et al. Transmural pressure measurements. Importance in the assessment of pulmonary hypertension in obstructive sleep apneas. Chest 1989, 95:338-342.
56. Tilkian A.G., Guilleminault C., Schroeder J.S., et al. Hemodynamics in sleep-induced apnea. Studies during wakefulness and sleep. Ann Intern Med 1976, 85:714-719.
57. Kohler M., Stradling J.R. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010, 7:677-685.
58. Sajkov D., Wang T., Saunders N.A., et al. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2002, 165:152-158.
59. Arias M.A., Garcia-Rio F., Alonso-Fernandez A., et al. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J 2006, 27:1106-1113.
60. MacGregor A.J., Canavan R., Knight C., et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 2001, 40:453-459.
61. Mukerjee D., St George D., Coleiro B., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003, 62:1088-1093.
62. Mathai S.C., Hummers L.K., Champion H.C., et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009, 60:569-577.
63. Le Pavec J., Girgis R.E., Lechtzin N., et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011, 63:2456-2464.
64. Campo A., Mathai S.C., Le Pavec J., et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010, 182:252-260.
65. Budhiraja R., Tuder R.M., Hassoun P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 2004, 109:159-165.
66. Hassoun P.M., Mouthon L., Barbera J.A., et al. Inflammation, growth factors, and pulmonary vascular remodeling. JAm Coll Cardiol 2009, 54:S10-S19.
67. Archer S., Michelakis E. The mechanism(s) of hypoxic pulmonary vasoconstriction: potassium channels, redox O(2) sensors, and controversies. News Physiol Sci 2002, 17:131-137.
68. Enson Y., Giuntini C., Lewis M.L., et al. The influence of hydrogen ion concentration and hypoxia on the pulmonary circulation. JClin Invest 1964, 43:1146-1162.
69. 2 at high altitude. JAppl Physiol 1976, 40:96-100.
70. Tillie-Leblond I., Marquette C.H., Perez T., et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006, 144:390-396.
71. Rizkallah J., Man S.F., Sin D.D. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2009, 135:786-793.
72. Swigris J.J., Olson A.L., Huie T.J., et al. Increased risk of pulmonary embolism among us decedents with sarcoidosis from 1988 to 2007. Chest 2011, 140:1261-1266.
73. Panos R.J., Mortenson R.L., Niccoli S.A., et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990, 88:396-404.
74. Barbera J.A., Riverola A., Roca J., et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994, 149:423-429.
75. Peinado V.I., Barbera J.A., Abate P., et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 159:1605-1611.
76. Santos S., Peinado V.I., Ramirez J., et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:1250-1256.
77. Vignola A.M., Chanez P., Chiappara G., et al. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med 1997, 156:591-599.
78. Beghe B., Bazzan E., Baraldo S., et al. Transforming growth factor-beta type ii receptor in pulmonary arteries of patients with very severe COPD. Eur Respir J 2006, 28:556-562.
79. Swigris J.J., Olson A., Shlobin O.A., et al. Heart rate recovery after 6MWT predicts pulmonary hypertension in patients with IPF. Respirology 2011, 16:439-445.
80. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. NEngl J Med 2004, 351:1425-1436.
81. Sugerman H.J., Baron P.L., Fairman R.P., et al. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg 1988, 207:604-613.
82. Nunes H., Humbert M., Capron F., et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006, 61:68-74.
83. Gluskowski J., Hawrylkiewicz I., Zych D., et al. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990, 3:403-407.
84. Le Pavec J., Lorillon G., Jais X., et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012, 142:1150-1157.
85. Vonbank K., Ziesche R., Higenbottam T.W., et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003, 58:289-293.
86. Roger N., Barbera J.A., Roca J., et al. Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997, 156:800-806.
87. Blanco I., Gimeno E., Munoz P.A., et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010, 181:270-278.
88. Blanco I., Santos S., Gea J., et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 2013, Available at:, Accessed September 10, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23429918.
89. Rietema H., Holverda S., Bogaard H.J., et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008, 31:759-764.
90. Collard H.R., Anstrom K.J., Schwarz M.I., et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007, 131:897-899.
91. Zisman D.A., Schwarz M., Anstrom K.J., et al. Acontrolled trial of sildenafil in advanced idiopathic pulmonary fibrosis. NEngl J Med 2010, 363:620-628.
92. Stolz D., Rasch H., Linka A., et al. Arandomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008, 32:619-628.
93. Badesch D.B., Feldman J., Keogh A., et al. Aries-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012, 30:93-99.
94. Raghu G., Million-Rousseau R., Morganti A., et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled music trial. Eur Respir J 2013, Available at:, Accessed September 10, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23682110.
95. Naeije R., Melot C., Mols P., et al. Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease. Am Rev Respir Dis 1982, 125:1-5.
96. Archer S.L., Mike D., Crow J., et al. Aplacebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996, 109:750-755.
97. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002, 360:895-900.
98. Dernaika T.A., Beavin M., Kinasewitz G.T. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010, 79:377-382.